NCT07021898View on ClinicalTrials.gov

A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors.

PHASE1RecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

August 6, 2025

Primary Completion Date

August 31, 2028

Study Completion Date

December 31, 2028

Conditions
Metastatic Solid Tumors
Interventions
DRUG

ERAS-4001

ERAS-4001 Administered orally

DRUG

ERAS-4001 in combination

ERAS-4001 Administered orally and in combination with either Keytruda (pembrolizumab) via IV administration or Vectibix (panitumumab) via IV administration.

Trial Locations (4)

32703

RECRUITING

Sarah Cannon Research Institute (SCRI) Oncology Partners, Nashville

75039

RECRUITING

NEXT Oncology, Irving

77030

RECRUITING

The University of Texas MD Anderson Cancer Center, Houston

78229

RECRUITING

NEXT Oncology, San Antonio

All Listed Sponsors
lead

Erasca, Inc.

INDUSTRY